Vertex: YOY Decline In Q4 Earnings Expected, But Revenue Continues To Shine

Terry Chrisomalis
Investing Group Leader

Summary

  • Expectation is a decline in Vertex's earnings, but double-digit revenue growth should continue with the newly approved non-opioid drug JOURNAVX and CF franchise expansion.
  • JOURNAVX, the first non-opioid oral pain signal inhibitor approved in over 20 years, targets a large market, potentially boosting Vertex's revenue significantly over time.
  • The company's CF franchise continues to expand with new approvals and treatments, including TRIKAFTA, ALYFTREK, and VX-522, targeting a broader patient base.
  • Despite financial risks, Vertex's strategic advancements in pain management with JOURNAVX and CF treatments positions it for long-term growth and potential investor gains.
  • Looking for a portfolio of ideas like this one? Members of Biotech Analysis Central get exclusive access to our subscriber-only portfolios. Learn More »

Exterior view of Campus Biotech, Geneva, Switzerland

HJBC/iStock Editorial via Getty Images

Vertex Pharmaceuticals (NASDAQ:VRTX) is expected to report its Q4 and full year 2024 results on February 10th of 2024. The expectations are that its earnings are going to decline, but it revenues are still

This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you read here and would like to subscribe to, I'm currently offering a two-week free trial period for subscribers to take advantage of. My service offers a deep-dive analysis of many pharmaceutical companies. The Biotech Analysis Central SA marketplace is $49 per month, but for those who sign up for the yearly plan will be able to take advantage of a 33.50% discount price of $399 per year.

This article was written by

Terry Chrisomalis
13.55K Followers

Terry Chrisomalis is a private investor in the Biotech sector with years of experience utilizing his Applied Science background to generate long term value from Healthcare.

He is the author of the investing group Biotech Analysis Central which contains a library of 600+ Biotech investing articles, a model portfolio of 10+ small and mid-cap stocks with deep analysis for each, live chat, and a range of analysis and news reports to help Healthcare investors make informed decisions.

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

About VRTX Stock

SymbolLast Price% Chg
Market Cap
PE
Yield
Rev Growth (YoY)
Short Interest
Prev. Close
Compare to Peers

More on VRTX

Related Stocks

SymbolLast Price% Chg
VRTX
--
Compare

Trending Analysis

Trending News